31 March 2014Kate Alzapiedi

Copyright compliance in the life sciences industry

Now that the rapid exchange of scientific research and product information across international borders has become commonplace, rights holders and users of published material face an increasingly complex set of issues involving reuse rights, permissions, restrictions and fees.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Merck KGaA agrees $11.3bn deal in major life sciences expansion

26 June 2026 Deal is aimed at strengthening German company’s presence across high-growth life sciences markets by adding a portfolio of advanced research and analytical technologies.

Americas

Pfizer’s US Paxlovid patent fight turns on a single error

25 June 2026 The Federal Circuit has brought Paxloid’s infringement case to an end, serving as a reminder that even minor changes to patent language can have major consequences.

Biotechnology

Novartis and Eli Lilly sign separate $1.9bn novel drug deals

25 June 2026 Novartis will work with a US biotech company on new cancer therapies, while Lilly has partnered with a Chinese biopharma firm to develop new medicines.

More features

‘Blatant imitation’: Indian court blocks copycat pharma branding

Kirkland & Ellis adds leading barrister in London

Kilpatrick adds tech patent litigator and China expert to Chicago office

Litigator from Brown Rudnick moves firms to chair practice

Patent office fee increases: What applicants must know

IndiaMart v CDSCO: A test of intermediary liability

Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks

Arnold & Porter adds tech litigator in San Francisco

Copyright compliance in the life sciences industry

More on this story

Editor's picks

Editor's picks

More features